Xiaoyi Sean Hu
MD Student with Scholarly Concentrations in Clinical Research, Molecular Basis of Medicine, expected graduation Spring 2025
All Publications
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Leukemia research
2024; 139: 107479
View details for DOI 10.1016/j.leukres.2024.107479
View details for PubMedID 38492495